Antisense Oligonucleotide Therapy for ALS
What You Need to Know Before You Apply
What is the purpose of this trial?
This research project entails delivery of a personalized antisense oligonucleotide (ASO) drug designed for a single participant with amyotrophic lateral sclerosis (ALS) due to a pathogenic variant in TARDBP.
Are You a Good Fit for This Trial?
This trial is for a single person diagnosed with ALS (Lou Gehrig's disease) who has a specific harmful change in the TARDBP gene. The treatment is personalized just for this individual.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- nL-TARDB-002
Trial Overview
A custom-made antisense oligonucleotide drug called nL-TARDB-002, designed to target the participant’s unique genetic mutation causing their ALS, will be given and its effects monitored.
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Find a Clinic Near You
Who Is Running the Clinical Trial?
n-Lorem Foundation
Lead Sponsor
Thomas Jefferson University
Collaborator
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.